CYRNQ yields 2000000.00% · PFE yields 6.13%● Live data
📍 CYRNQ pulled ahead of the other in Year 1
Combined, CYRNQ + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYRNQ + PFE for your $10,000?
Cyren Ltd., together with its subsidiaries, provides cloud delivered Software-as-a-Service (SaaS) cybersecurity solutions that protect businesses, their employees, and customers against threats from email, files, and the web. It provides Cyren threat detection services, which include email security engine that offers anti-spam inbound and outbound, IP reputation, and virus outbreak detection services; malware detection engine that is used to protect email applications; Web security engine, which is used by customers to provide URL classification for web browser filtering and safe search capabilities; and threat analysis services to detect advanced cyber threats. The company also provides Cyren threat intelligence data products, which include real-time phishing intelligence, malware file intelligence, IP reputation intelligence, malware URL intelligence, and Zombie host intelligence for threat detection, threat hunting, and incident response. In addition, it offers Cyren enterprise email security products, including Cyren Email Security, a cloud-based secure email gateway; and Cyren Inbox Security, an anti-phishing and remediation product for Microsoft 365. The company sells its products through direct and indirect channels, including distributors, value added resellers, and managed service providers to enterprise customers and original equipment manufacturers. It has operations in the United States, Germany, other European countries, the Asia Pacific, Israel, and internationally. The company was formerly known as Commtouch Software Ltd. and changed its name to Cyren Ltd. in January 2014. Cyren Ltd. was incorporated in 1991 and is based in Herzliya, Israel.
Full CYRNQ Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.